Taking stock of the drug industry, from the lab to the medicine chestFebruary 23, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer J. Scott Applewhite/AP STAT+ | Canadian board member resigns, skewers government for failing to follow through on containing drug costs "When government adds it voice to industry, all that lies before the regulator is an endless tunnel with no light," wrote Matthew Herder. By Ed Silverman STAT+ | Lawmakers urge U.S. patent office to scrutinize Merck over 'abuse' of the system Lawmakers are raising questions about the patent strategies deployed by Merck for Keytruda, its cancer drug. By Ed Silverman 'A slippery slope': A looming nationwide abortion pill ban could undermine the entire drug approval system If an attempted ban on the abortion pill prevails in court, it could undermine the FDA and the country's infrastructure for evaluating drugs. By Eric Boodman Photo by Phil Walter/Getty Images Opinion: The Supreme Court doesn't belong in your medicine cabinet Health care leaders need to speak out about the repercussions of taking away medical sovereignty from 40 million women. By Paul J. Hastings STAT+ | DaVita faces another probe over ties to kidney care charity The D.C. attorney general is investigating the dialysis provider DaVita and its ties to the nonprofit American Kidney Fund. By Bob Herman Listen: Vertex vs. insurers, Moderna's future, & biotech's long winter STAT's Ed Silverman joins us to explain how an escalating fight between Vertex and insurers has left patients caught in the middle. By Damian Garde and Meg Tirrell and Adam Feuerstein More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments